There's an ongoing patent litigation on Teva’s Azilect - there's a Paragraph IV challenge and a 30 month stay on approval till Nov 2013 (or a district court decision).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.